Virpax And MedPharm Advance Diclofenac Spray

Transdermal Osteoarthritis Treatment To Be Submitted Via 505(b)(2) Pathway In US

 
• By Dave Wallace

Virpax Pharmaceuticals and partner MedPharm say they have made progress towards filing through the US 505(b)(2) hybrid pathway a diclofenac spray for treating osteoarthritis of the knee.

Knee painful - skeleton x-ray, 3D Illustration medical concept
Epoladerm is intended to help manage osteoarthritis of the knee • Source: Shutterstock

More from Value Added Medicines

More from Products